These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 28522744

  • 1. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.
    Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH.
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [Abstract] [Full Text] [Related]

  • 2. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.
    J Clin Oncol; 2010 Nov 01; 28(31):4714-21. PubMed ID: 20876421
    [Abstract] [Full Text] [Related]

  • 3. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.
    van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH.
    Eur J Nucl Med Mol Imaging; 2017 Jan 01; 44(1):71-80. PubMed ID: 27511188
    [Abstract] [Full Text] [Related]

  • 4. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec 01; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

  • 5. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 6. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 05; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 7. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
    Jingu K, Kaneta T, Nemoto K, Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Takai Y, Takahashi S, Yamada S.
    Int J Clin Oncol; 2010 Apr 05; 15(2):184-90. PubMed ID: 20217449
    [Abstract] [Full Text] [Related]

  • 8. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan 05; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 9. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH.
    Eur J Cancer; 2007 Jun 05; 43(9):1385-91. PubMed ID: 17512192
    [Abstract] [Full Text] [Related]

  • 10. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
    Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH.
    Cancer; 2016 Jul 01; 122(13):2083-90. PubMed ID: 27152857
    [Abstract] [Full Text] [Related]

  • 11. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ.
    Ann Nucl Med; 2018 Apr 01; 32(3):165-174. PubMed ID: 29332233
    [Abstract] [Full Text] [Related]

  • 12. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS.
    J Surg Oncol; 2014 Apr 01; 109(5):472-7. PubMed ID: 24301552
    [Abstract] [Full Text] [Related]

  • 13. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 01; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 14. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 01; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 15. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH.
    J Clin Oncol; 2021 Sep 01; 39(25):2803-2815. PubMed ID: 34077237
    [Abstract] [Full Text] [Related]

  • 16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul 01; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 17. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 01; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 18. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 19. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):358-63. PubMed ID: 17532577
    [Abstract] [Full Text] [Related]

  • 20. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
    van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH.
    J Nucl Med; 2016 May 01; 57(5):691-700. PubMed ID: 26795288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.